241 related articles for article (PubMed ID: 21907623)
1. Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study.
Schulte-Baukloh H; Mürtz G; Heine G; Austin P; Miller K; Michael T; Strugala G; Knispel HH
J Pediatr Urol; 2012 Aug; 8(4):386-92. PubMed ID: 21907623
[TBL] [Abstract][Full Text] [Related]
2. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
Madersbacher H; Mürtz G; Alloussi S; Domurath B; Henne T; Körner I; Niedeggen A; Nounla J; Pannek J; Schulte-Baukloh H; Schultz-Lampel D; Bock P; Strugala G
BJU Int; 2009 Mar; 103(6):776-81. PubMed ID: 19007380
[TBL] [Abstract][Full Text] [Related]
3. Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis.
Schulte-Baukloh H; Mürtz G; Henne T; Michael T; Miller K; Knispel HH
BJU Int; 2006 Feb; 97(2):355-8. PubMed ID: 16430646
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity--a retrospective study.
Grigoleit U; Mürtz G; Laschke S; Schuldt M; Goepel M; Kramer G; Stöhrer M
Eur Urol; 2006 Jun; 49(6):1114-20; discussion 1120-1. PubMed ID: 16542772
[TBL] [Abstract][Full Text] [Related]
5. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
Stöhrer M; Mürtz G; Kramer G; Schnabel F; Arnold EP; Wyndaele JJ;
Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
Alloussi S; Mürtz G; Braun R; Gerhardt U; Heinrich M; Hellmis E; Horn W; Marschall-Kehrel D; Niklas K; Raabe M; Rössler T; Seibt B; Siemer S; Schultz-Lampel D; Walter H; Wiedeking B; Alloussi S; Bock P; Strugala G; Madersbacher H
BJU Int; 2010 Aug; 106(4):550-6. PubMed ID: 20002668
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
8. Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity.
Ghalayini IF; Al-Ghazo MA; Elnasser ZA
Int Urol Nephrol; 2009 Dec; 41(4):805-13. PubMed ID: 19184509
[TBL] [Abstract][Full Text] [Related]
9. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.
McKeage K
Clin Drug Investig; 2013 Jan; 33(1):71-91. PubMed ID: 23288694
[TBL] [Abstract][Full Text] [Related]
10. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Giannantoni A; Mearini E; Del Zingaro M; Porena M
Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of propiverine hydrochloride extended-release compared with immediate-release in patients with neurogenic detrusor overactivity.
Stöhrer M; Mürtz G; Kramer G; Warnack W; Primus G; Jinga V; Manu-Marin A; Calomfirescu N; Strugala G
Spinal Cord; 2013 May; 51(5):419-23. PubMed ID: 23338657
[TBL] [Abstract][Full Text] [Related]
12. Supratrigonal cystectomy with Hautmann pouch as treatment for neurogenic bladder in spinal cord injury patients: long-term functional results.
Gobeaux N; Yates DR; Denys P; Even-Schneider A; Richard F; Chartier-Kastler E
Neurourol Urodyn; 2012 Jun; 31(5):672-6. PubMed ID: 22532256
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder.
Watanabe M; Yamanishi T; Honda M; Sakakibara R; Uchiyama T; Yoshida K
Int J Urol; 2010 Nov; 17(11):931-6. PubMed ID: 20969642
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
15. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity.
Kim SW; Choi JH; Lee YS; Han SW; Im YJ
Urology; 2014 Dec; 84(6):1480-4. PubMed ID: 25432842
[TBL] [Abstract][Full Text] [Related]
16. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder.
Jünemann KP; Hessdörfer E; Unamba-Oparah I; Berse M; Brünjes R; Madersbacher H; Gramatté T
Urol Int; 2006; 77(4):334-9. PubMed ID: 17135784
[TBL] [Abstract][Full Text] [Related]
17. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
Marschall-Kehrel D; Feustel C; Persson de Geeter C; Stehr M; Radmayr C; Sillén U; Strugala G
Eur Urol; 2009 Mar; 55(3):729-36. PubMed ID: 18502028
[TBL] [Abstract][Full Text] [Related]
18. Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre.
Del Popolo G; Filocamo MT; Li Marzi V; Macchiarella A; Cecconi F; Lombardi G; Nicita G
Eur Urol; 2008 May; 53(5):1013-19. PubMed ID: 17950989
[TBL] [Abstract][Full Text] [Related]
19. Botulinum-A toxin: solo treatment for neuropathic noncompliant bladder.
Neel KF; Soliman S; Salem M; Seida M; Al-Hazmi H; Khatab A
J Urol; 2007 Dec; 178(6):2593-7; discussion 2597-8. PubMed ID: 17945300
[TBL] [Abstract][Full Text] [Related]
20. Effect of onabotulinumtoxinA treatment on symptoms and urodynamic findings in pediatric neurogenic bladder.
Kask M; Rintala R; Taskinen S
J Pediatr Urol; 2014 Apr; 10(2):280-3. PubMed ID: 24095686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
